ClinicalTrials.gg
RecruitingNCT05675787Updated Jul 11, 2024

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

A Phase 2 interventional study of Medroxyprogesterone acetate + Atorvastatin in Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to female participants aged 17 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
17 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Endometrial Hyperplasia with a site in China — 14 open to participants now, 15 under way, 5 of them phase 3. Endometrial Hyperplasia · China.

Planned enrollment
8th of 19
82 · median 75
Started
2023
with 2 others
Phase 2
7 of 22
6 open now
Primary completion
2025-08
later than 2 of 14 live
Registered
11th of 22
by date
Lead sponsor
4 of 22
Peking University People's Hospital

Among the 22 studies in Endometrial Hyperplasia with a site in China, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 2 of the 14 other live ones, and was the 11th registered.

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Open to participants now

14 of the 22 studies in Endometrial Hyperplasia with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 17 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Endometrial Hyperplasia with a site in China, or all of them as a file.
02

Study summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Read the detailed description

After diagnosed of AEH or EEC by hysteroscopy, patients meet the study criteria will be enrolled. The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue was detected by Raman scattering instrument. And Age, height, weight, waistline, blood pressure, basic history of infertility and family cancer will be collected. Blood tests, including fasting blood glucose (FBG), fasting insulin (FINS), blood lipids, sex hormone levels, anti-müllerian hormone (AMH) and renal/liver function tests will be performed before treatment to evacuate their basic conditions. Each subject will receive body fat testing by Inbody 770.

Patients will receive MPA (Medroxyprogesterone acetate) 250-500 mg by mouth daily plus atorvastatin 20mg by mouth daily for at least 3 months. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of higher pathological progression, or myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR. Patients with PD will be recommended for hysterectomy.

For patients remained SD after 9 months of treatment but refused hysterectomy, a multiple disciplinary discussion would be held for individual case, and alternative treatment would be given. Three months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for at least 1 year.

03

Conditions studied

  • Atypical Endometrial Hyperplasia
  • Endometrial Carcinoma Stage I

Keywords

  • Endometrial Carcinoma
  • Atypical Endometrial Hyperplasia
04

Who can participate

Ages eligible
17 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy;
  • No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
  • Have a desire for remaining reproductive function or uterus
  • Good compliance with adjunctive treatment and follow-up

Exclusion criteria

Exclusion Criteria:

  • or contradiction for using MPA or atorvastatin
  • Pregnancy or potential pregnancy
  • Confirmed diagnosis of any cancer in reproductive system
  • Already diagnosed with hyperlipidemia and using lipid-lowering drugs
  • Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
  • Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
  • With other factors of reproductive dysfunction;
  • Strong request for uterine removal or other conservative treatment
  • Smoker (>15 cigarettes a day)
  • Drinker (>20 grams a day)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Experimental group

    MPA + Atorvastatin

    Drug: Medroxyprogesterone acetate + Atorvastatin

  • No intervention
    Control groups

    MPA

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological cumulative complete response rate;

    3 to 4 months: From date of initial therapy until the date of CR or date of hysterectomy,

    Time frame: assessed up to 4 months

Secondary outcomes

  1. Pathological cumulative complete response rate;

    From 6 to 8 months; From date of initial therapy until the date of CR or date of hysterectomy,

    Time frame: assessed up to 8 months

  2. The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue

    The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion

    Time frame: assessed up to 4 months

  3. Overall complete response rate

    Pathological response duration

    Time frame: up to 2 years

  4. Pathological response rate classified by different blood lipid level

    Pathological response rate classified by different blood lipid level

    Time frame: up to 2 years;

  5. Relapse rate

    Relapse rate

    Time frame: up to 15 months after the end of treatment

  6. Pregnancy rate

    Pregnancy rate

    Time frame: up to 15 months after the end of treatment

  7. Toxic Side Effect

    Toxicity evaluation according to CTCAE 5.0 version.

    Time frame: up to 3 months after the end of treatment

07

Study locations

1 of 1 sites recruiting
  • Wang Jianliu
    Peking, Beijing 100044, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Aug 2025, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 9, 2023
StartActual
Jan 6, 2023
Primary completionEst.
Aug 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05675787
Responsible party
Wang Jianliu (Professor, Doctoral supervisor, Chief physician, Vice President, Peking University People's Hospital) — Principal investigator
First posted
Jan 9, 2023
Start date
Jan 6, 2023
Primary completion
Aug 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Jul 11, 2024

Study contacts

WANG JIANLIU, PhD/MD
Contact
wangjianliu1203@163.com
+861088324383
HE YIJIAO, PhD
Contact
heyijiao2017@pku.edu.cn
+8618301512017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Medroxyprogesterone Acetate · Atorvastatin

Start the discussion